The Lancet

When to and when not to use machine learning in risk prediction models

Machine learning for health data science, fuelled by proliferation of data and reduced computational costs, has garnered ...
AHA/ASA Journals

Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association

There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as ...
IEEE

Exploratory Modeling Strategies for Robust Medical Condition Classification Using Machine Learning

Abstract: Machine learning has great opportunities in early detection of diseases and better patient health treatment. This paper provides a predictive model of medical conditions based on a Kaggle ...
IEEE

Machine Learning Techniques to Improve the Cognitive Workload Classification Using Multimodal Sensors’ Data

Abstract: Using machine learning applied to multimodal physiological data allows the classification of cognitive workload (low, moderate, or high load) during task performance. However, current ...
Medical Xpress

Machine learning can predict patients' responses to antidepressants—while disentangling drug and placebo effects

Depression is one of the most widespread mental health disorders worldwide, affecting approximately 4% of the global population. It is characterized by a persistent low mood, disruptions in typical ...
Houston Chronicle

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking deep concerns among agency staffers and outside experts, with some saying the poorly defined effort ...
Yahoo

Legal questions swirl around FDA's new expedited drug program, including who should sign off

WASHINGTON (AP) — The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the ...
Hosted on MSN

Exclusive - US FDA delays two drug reviews in new voucher program after safety, efficacy concerns

Jan 15 (Reuters) - The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track program after agency scientists flagged safety and ...